The recent agreement between Freenome and Biognosys suggests a role for proteomics as developers of genomic-based cancer detection tests look beyond ctDNA.
Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.
The agreement brings together Biognosys' Spectronaut Pulsar DIA software and Waters' SONAR data-independent acquisition mass spectrometry method.
The company said it plans to use the funds to extend its commercial operations and develop new products broadly aimed at the life sciences research market.
As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.
The agreement involves Thermo Fisher's Orbitrap mass specs and Biognosys' Spectronaut Pulsar software for data-independent acquisition studies.
The company has licensed the Limited Proteolysis technology developed by ETH Zurich Professor Paola Picotti, which can assess proteome-wide structural changes.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The firm, which will open a Boston office at the end of Q1, did not disclose the amount raised but said it was in the "mid-single-digit millions" of dollars.
The effort will use Biognosys' HRM method to complement its MALDI-TOF approach to biomarker work, a company official said.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
The Wall Street Journal looks into the cost of new gene therapies.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.